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Abstract SB203580 is a recognised inhibitor of p38-MAPKs.
Here, we investigated the effects of SB203580 on cardiac
SAPKs/JNKs. The IC50 for inhibition of p38-MAPK stimulation
of MAPKAPK2 was approximately 0.07 WM, whereas that for
total SAPK/JNK activity was 3^10 WM. SB203580 did not
inhibit immunoprecipitated JNK1 isoforms. Three peaks of
SAPK/JNK activity were separated by anion exchange chroma-
tography, eluting in the isocratic wash (44 kDa), and at 0.08 M
(46 and 52 kDa) and 0.15 M NaCl (54 kDa). SB203580 (10 WM)
completely inhibited the 0.15 M NaCl activity and partially
inhibited the 0.08 M NaCl activity. Since JNK1 antibodies
immunoprecipitate the 46 kDa activity, this indicates that
SB203580 selectively inhibits 52 and 54 kDa SAPKs/JNKs.
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1. Introduction
The three well-characterised subfamilies of the mitogen-ac-
tivated protein kinase (MAPK) superfamily are the extracel-
lularly responsive kinases (ERKs), the c-Jun N-terminal kin-
ases (JNKs) which are also known as stress-activated protein
kinases (SAPKs), and the p38-MAPKs [1^3]. In perfused
heart, p38-MAPK is activated by ischaemia and ischaemia/
reperfusion, but the SAPKs/JNKs are activated only during
the reperfusion phase following ischaemia [4]. SAPKs/JNKs
are also powerfully activated in neonatal ventricular myocytes
by cellular stresses [5]. Substrates for the MAPKs include
MAPK-activated protein kinase 2 (MAPKAPK2) and the
transcription factor c-Jun. MAPKAPK2 is preferentially
phosphorylated by p38-MAPK [6] and c-Jun is a substrate
for SAPKs/JNKs [7], although both are phosphorylated by
ERKs in vitro [8,9]. SB203580 is a recognised inhibitor of
p38-MAPK(K) and p38-MAPKL [10^13]. It does not inhibit
the other p38-MAPKs so far identi¢ed [12,13], and it was
reported to have no e¡ect on ERK or SAPK/JNK activities
in vitro [11]. It has been proposed that SB203580 may be
particularly useful in delineating the roles of p38-MAPK(K)
and p38-MAPKL in cellular responses [13]. We have re-exam-
ined the inhibitory e¡ects of SB203580 on cardiac MAPKs.
Here, we present evidence that two c-Jun N-terminal kinases
(SAPKs/JNKs), activated in adult perfused hearts and neo-
natal ventricular myocytes, are inhibited by SB203580.
2. Materials and methods
2.1. Heart perfusions and primary culture of ventricular myocytes
Adult rat hearts were perfused and homogenates prepared as pre-
viously described [14]. Neonatal rat ventricular myocytes were cul-
tured as described in [15]. Serum was withdrawn for 24 h, myocytes
were exposed to 0.5 M sorbitol (30 min) in the absence or presence of
up to 10 WM SB203580 and samples were prepared as described in [5].
2.2. Fast protein liquid chromatography of MAPKs and MAPKAPK2
Proteins (0.5 ml of extract) were separated by FPLC. SAPKs/JNKs
were separated on a Mono Q HR5/5 column as previously described
[5], except that the MAPKs were eluted using a 30 ml linear NaCl
gradient (0^0.5 M NaCl). They were assayed by the direct method
with myelin basic protein (MBP) or 0.5 mg/ml glutathione S-trans-
ferase-(GST-)c-Jun(1^135) as substrates, as previously described
[5,16,17] except that the assay mix contained 0.1% (v/v) dimethyl
sulphoxide or 10 WM SB203580 (¢nal concentrations). Samples of
fractions were taken for in-gel kinase assays as described in [5]. In
some experiments, fractions were pooled and concentrated by ultra-
¢ltration and prepared for immunoblot analysis [14]. For MAP-
KAPK2, proteins (0.5 ml) were applied to a Mono S HR5/5 column
and MAPKAPK2 was puri¢ed and assayed as described [14].
2.3. Immunoblotting and in-gel kinase assays
These methods are described in [14].
2.4. ‘Pull-down’ SAPK/JNK assays
GST-c-Jun(1^135) was used to ‘pull down’ total SAPKs/JNKs from
myocyte extracts as described in [5]. Pellets were washed in kinase
assay bu¡er (20 mM HEPES pH 7.7, 2.5 mM MgCl2, 0.1 mM
EDTA, 20 mM L-glycerophosphate) containing the ¢nal concentra-
tions of SB203580. The pellets were resuspended in 15 Wl kinase assay
bu¡er containing twice the ¢nal concentrations of SB203580 and
phosphorylation was initiated with 15 Wl of kinase assay Bu¡er con-
taining 20 WM ATP and 2 WCi [Q-32P]ATP. The assay was completed
as described in [5].
2.5. JNK1 immunokinase assays
JNK1 isoforms were immunoprecipitated from myocyte extracts as
described in [14] using antibodies from Santa Cruz. The pellets were
washed in kinase assay bu¡er containing the ¢nal concentrations of
SB203580. GST-c-Jun(1^135) in 15 Wl kinase assay bu¡er containing
twice the ¢nal concentrations of SB203580 was added and phos-
phorylation was initiated with 15 Wl of kinase assay bu¡er containing
20 WM ATP and 2 WCi [Q-32P]ATP. The assay was completed as
described in [5].
3. Results
3.1. Inhibition of MAPKAPK2 activation by SB203580
We ¢rst assessed the e¡ects of SB203580 on p38-MAPK
activation of MAPKAPK2 in neonatal myocytes. 0.5 M sor-
bitol (30 min) induced a large (approximately 16-fold) increase
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in MAPKAPK2 activity (Fig. 1A), which was inhibited by
SB203580 with an IC50 of 0.07 WM (Fig. 1A).
3.2. SB203580 inhibition of c-Jun N-terminal kinases
We studied the e¡ects of SB203580 on SAPKs/JNKs acti-
vated in neonatal rat ventricular myocytes by 0.5 M sorbitol
(30 min). Total SAPK/JNK activities, measured using ‘pull-
down’ assays with GST-c-Jun(1^135) [5], were inhibited by
SB203580 with an IC50 of 3^10 WM (Fig. 1B, upper panel).
The SAPK/JNKs are derived from at least three genes (JNK1^
3), each of which produces alternatively spliced transcripts
encoding proteins of approximately 46 kDa and 54 kDa
[18]. Antibodies to JNK1 isoforms immunoprecipitate almost
all of the cardiac 46 kDa activity and a proportion of the 52/
54 kDa activity [5]. SB203580 (at concentrations of up to 30
WM) did not inhibit these immunoprecipitated isoforms (Fig.
1B, lower panel). Antibodies to JNK2 isoforms have not
proved suitable for immunoprecipitation (results not shown),
and antibodies to JNK3 are not available. We therefore par-
tially puri¢ed the di¡erent isoforms from adult rat hearts sub-
jected to ischaemia/reperfusion (Fig. 2A), and from neonatal
ventricular myocytes exposed to 0.5 M sorbitol (30 min) (Fig.
2B) by Mono Q FPLC. Three peaks of activity were detected,
eluting in the isocratic wash (results not shown) and at ap-
proximately 0.08 M and 0.15 M NaCl (Fig. 2). As shown on
in-gel kinase assays (GST-c-Jun(1^135) as substrate), the peak
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Fig. 1. A: Inhibition of MAPKAPK2 activation by SB203580 in
primary cultures of rat ventricular myocytes. MAPKAPK2 activities
were assayed from myocytes exposed to 0.5 M sorbitol (30 min) in
the presence of 0.1% DMSO containing up to 10 WM SB203580. B:
SAPKs/JNKs were assayed by the ‘pull-down’ method (upper panel)
or by a JNK1 immunokinase assay (lower panel) in the presence of
increasing concentrations of SB203580. These experiments were re-
peated two times with similar results.
Fig. 2. Inhibition of partially puri¢ed SAPKs/JNKs by SB203580.
A: Isolated hearts were subjected to 20 min ischaemia followed by
10 min reperfusion. B: Myocytes were exposed to 0.5 M sorbitol
for 30 min. In the upper panels, MAPKs were separated by Mono
Q FPLC and fractions were assayed for SAPK/JNK activity in the
absence (b, solid line) or presence (R, dashed line) of 10 WM
SB203580. The NaCl gradient is shown by the dotted line. In the
lower panels, fractions with SAPK/JNK activity were assayed by
the in-gel kinase method with GST-c-Jun(1-135) as substrate. The
experiment was repeated a further three times with similar results.
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eluting at 0.08 M NaCl contained two SAPK/JNK activities
of approximately 46 and 52 kDa relative molecular mass, and
the peak eluting at 0.15 M NaCl contained a 54 kDa SAPK/
JNK (Fig. 2A,B, lower panels). The isocratic wash contained
a 44 kDa SAPK/JNK activity (results not shown). No other
SAPK/JNK activities were eluted by up to 0.5 M NaCl. No 38
kDa activity was detected in any of the three SAPK/JNK
peaks. SB203580 (10 WM) completely inhibited the SAPK/
JNK activity eluting at 0.15 M NaCl and partially inhibited
(approximately 50%) the SAPK/JNK activity eluting at 0.08
M NaCl (Fig. 2A,B, upper panels), but had no e¡ect on the
SAPK/JNK activity eluting in the isocratic wash (results not
shown). Hyperosmotic shock also activates the ERKs in ven-
tricular myocytes [5] which eluted at approximately 0.20 M
(fractions 29^31) and 0.25 M NaCl (fractions 36 and 37), and
were detected as minor bands in the in-gel assays using GST-
c-Jun(1^135) as substrate (Fig. 2B, lower panel). Neither peak
of ERK activity was inhibited by 10 WM SB203580 (results
not shown), consistent with published data [11].
3.3. Separation of p38-MAPK and c-Jun N-terminal kinases by
Mono Q FPLC
We studied the elution pro¢le of cardiac p38-MAPK on
Mono Q FPLC using extracts of hearts subjected to ischae-
mia/reperfusion. Using in-gel kinase assays with GST-MAP-
KAPK2(46^400) as substrate, kinase activities were detected
in fraction 4 (isocratic wash, 40 kDa), fractions 34^36 (0.25 M
NaCl, 42 kDa), fractions 40^42 (0.29 M NaCl, 44 kDa) and
fraction 56 (0.4 M NaCl, 38 kDa) (Fig. 3A). The elution of
p38-MAPK at approximately 0.4 NaCl is consistent with pub-
lished data [5,6,17]. Fractions 4, 18^20 (V0.08 M NaCl), 28^
30 (V0.15 M NaCl) and fractions 54^56 (V0.4 M NaCl)
were concentrated by ultra¢ltration and were analysed by
immunoblotting with antibodies from Santa Cruz (Fig. 3B).
Antibodies to JNK1 detected bands in fraction 4 (44 kDa),
fractions 18^20 (46 and 52 kDa), and fractions 28^30
(54 kDa), but not fractions 54^46 (Fig. 3B, upper panel). In
contrast, a p38-MAPK antibody detected a single 38 kDa
band in fractions 54^56 (Fig. 3B, lower panel). These experi-
ments show that p38-MAPK elutes from Mono Q FPLC
at higher concentrations of NaCl than the SAPKs/JNKs
and is not responsible for the c-Jun N-terminal kinase activ-
ities in fractions 18^20 and 28^30 which are inhibited by
SB203580.
4. Discussion
Although SB203580 is widely accepted as a speci¢c inhib-
itor of p38-MAPK(K) and p38-MAPKL [10^13], we have
shown here that it inhibits at least two kinases which phos-
phorylate the N-terminal transactivation domain of c-Jun
(Fig. 1B, Fig. 2A,B). These kinases have a similar apparent
relative molecular mass to established SAPK/JNK isoforms
(approximately 52 and 54 kDa) (Fig. 2), and elute from
Mono Q columns at substantially lower NaCl concentrations
than p38-MAPK (Fig. 3A). Furthermore, no 38 kDa c-Jun N-
terminal kinase activity was detectable. These data indicate
that SB203580 is indeed inhibiting SAPK/JNK isoforms. Re-
cently, SB203580 was shown to inhibit certain epitope-tagged
human SAPK/JNK isoforms which were overexpressed and
immunoprecipitated from UV-treated COS-7 cells [19].
JNK2 isoforms were more susceptible to inhibition than
JNK1 isoforms and were inhibited by micromolar concentra-
tions of SB203580 [19]. Our data are consistent with inhibition
of JNK2-related isoforms. Importantly, although the IC50 for
inhibition of p38-MAPKs is (in our hands) 0.07 WM (Fig. 1A),
10 WM SB203580 is frequently used in order to establish the
involvement of p38-MAPK in cellular responses, a concentra-
tion which completely inhibits at least one other kinase in the
heart (54 kDa SAPK/JNK). Since many interventions that
activate p38-MAPK also activate SAPKs/JNKs [2], our data
suggest that caution should be exercised in the use of
SB203580 to implicate the participation of p38-MAPK in sig-
nalling pathways.
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Fig. 3. p38-MAPK elutes from Mono Q FPLC at a higher NaCl
concentration than SAPKs/JNKs. Adult perfused hearts were sub-
jected to 20 min ischaemia followed by 10 min reperfusion and the
MAPKs separated on Mono Q FPLC. A: All fractions were as-
sayed for MAPK activity by the in-gel kinase method with GST-
MAPKAPK2(46^400) as substrate. Only the fractions which con-
tained kinase activity are shown. The arrow to the right of the pan-
el shows the position of the 46 kDa molecular mass standard. B:
Fractions from the Mono Q FPLC column containing SAPK/JNK
or p38-MAPK activity were concentrated 7^15-fold by ultra¢ltration
and immunoblotted using antibodies to JNK1 (upper panel) or p38-
MAPK (lower panel). The experiment was repeated a further two
times with similar result.
A. Clerk, P.H. Sugden/FEBS Letters 426 (1998) 93^96 95
[5] Bogoyevitch, M.A., Ketterman, A.J. and Sugden, P.H. (1995)
J. Biol. Chem. 270, 29710^29717.
[6] Rouse, J., Cohen, P., Trigon, S., Morange, M., Alonso-Llama-
zares, A., Zamanillo, D., Hunt, T. and Nebreda, A.R. (1994) Cell
78, 1027^1037.
[7] Kyriakis, J.M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie,
E.A., Ahmad, M.F., Avruch, J. and Woodgett, J.R. (1994) Na-
ture 369, 156^160.
[8] Stokoe, D., Campbell, D.G., Nakielny, S., Hidaka, H., Leevers,
S.J., Marshall, C. and Cohen, P. (1992) EMBO J. 11, 3985^3994.
[9] Pulverer, B.J., Kyriakis, J.M., Avruch, J., Nikolakaki, E. and
Woodgett, J.R. (1991) Nature 353, 670^674.
[10] Lee, J.C., Laydon, J.T., McDonnell, P.C., Gallagher, T.F., Ku-
mar, S., Green, D., McNulty, D., Blumenthal, M.J., Heys, R.J.,
Landvatter, S.W., Strickler, J.E., McLaughlin, M.M., Siemens,
I.R., Fisher, S.M., Livi, G.P., White, J.R., Adams, J.L. and
Young, P.R. (1994) Nature 372, 739^746.
[11] Cuenda, A., Rouse, J., Doza, Y.N., Meier, R., Cohen, P., Gal-
lagher, T.F., Young, P.R. and Lee, J.C. (1995) FEBS Lett. 364,
229^233.
[12] Goedert, M., Cuenda, A., Craxton, M., Jakes, R. and Cohen, P.
(1997) EMBO J. 16, 3563^3571.
[13] Kumar, S., McDonnell, P.C., Gum, R.J., Hand, A.T., Lee, J.C.
and Young, P.R. (1997) Biochem. Biophys. Res. Commun. 235,
533^538.
[14] Clerk, A., Fuller, S.J., Michael, A. and Sugden, P.H. (1998)
J. Biol. Chem. 273 (in press).
[15] Bogoyevitch, M.A., Clerk, A. and Sugden, P.H. (1995) Biochem.
J. 309, 437^443.
[16] Bogoyevitch, M.A., Glennon, P.E. and Sugden, P.H. (1993)
FEBS Lett. 317, 271^275.
[17] Bogoyevitch, M.A., Glennon, P.E., Andersson, M.B., Clerk, A.,
Lazou, A., Marshall, C.J., Parker, P.J. and Sugden, P.H. (1994)
J. Biol. Chem. 269, 1110^1119.
[18] Gupta, S., Barrett, T., Whitmarsh, A.J., Cavanagh, J., Sluss,
H.K., DeŁrijard, B. and Davis, R.J. (1996) EMBO J. 15, 2760^
2770.
[19] Whitmarsh, A.J., Yang, S.-H., Su, M.S.-S., Sharrocks, A.D. and
Davis, R.J. (1997) Mol. Cell. Biol. 17, 2360^2371.
FEBS 20091 9-4-98
A. Clerk, P.H. Sugden/FEBS Letters 426 (1998) 93^9696
